Indications
Venetoclax is prescribed for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). In addition, it is administered in combination with azacitidine, decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults who are 75 years or older, or who have comorbidities that do not allow for intensive induction chemotherapy.
Pharmacodynamics
Venetoclax functions by inducing rapid and potent apoptosis in CLL cells, with effects observable within 24 hours, leading to potential tumor lysis syndrome. The drug selectively targets BCL2, exhibiting a manageable safety profile and inducing significant responses in patients with relapsed CLL or SLL, including those with poor prognostic features. Venetoclax has shown efficacy across various lymphoid malignancies, particularly in relapsed/refractory CLL with deletion 17p, achieving an overall response rate of approximately 80%. It does not significantly impact the cardiac QT interval.
Absorption
Upon multiple oral administrations after a meal, venetoclax reaches its maximum plasma concentration within 5 to 8 hours. The steady-state area under the curve (AUC) for venetoclax increases proportionally over a dose range of 150-800 mg. When taken with a low-fat meal, the steady-state maximum concentration (Cmax) is 2.1 ± 1.1 μg/mL, and AUC over 24 hours is 32.8 ± 16.9 μg·h/mL at a 400 mg daily dose. Compared to the fasted state, venetoclax exposure increases 3.4 times with a low-fat meal and 5.2 times with a high-fat meal. The Cmax and AUC increase by 50% with a high-fat meal relative to a low-fat meal. Consequently, it is recommended that venetoclax be taken with food.
Metabolism
In vitro studies reveal that venetoclax is predominantly metabolized by the cytochrome P450 enzymes CYP3A4/5.
Mechanism of Action
Venetoclax functions by targeting and inhibiting the BCL-2 protein, a key regulator within the B cell CLL/lymphoma 2 (BCL-2) family that plays a crucial role in regulating apoptosis, the process of programmed cell death. This family contains both proapoptotic and prosurvival proteins, which are vital for cellular regulation. Cancer cells often evade apoptosis by hindering this natural cell death mechanism. The development of navitoclax marked a significant breakthrough in selectively inhibiting prosurvival proteins, exhibiting clinical efficacy in certain BCL-2-dependent hematological cancers. Venetoclax offers a targeted approach by specifically inhibiting BCL-2 while sparing BCL-xL, thus promoting apoptosis without causing thrombocytopenia. It binds directly to the BCL-2 protein, displacing pro-apoptotic proteins, resulting in the permeabilization of the mitochondrial outer membrane and activation of caspase enzymes. In preclinical studies, venetoclax has demonstrated cytotoxic effects on tumor cells overexpressing BCL-2.
